Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 7/20 | 0.34 |
| ▸ | DRD2 | P14416 | 4/20 | 0.34 |
| ▸ | DRD1 | P21728 | 4/20 | 0.34 |
| ▸ | DRD4 | P21917 | 4/20 | 0.34 |
| ▸ | DRD5 | P21918 | 4/20 | 0.34 |
| ▸ | DRD3 | P35462 | 4/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4063484 | 0.82 | KIF11 (0.37) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL4038267 | 0.82 | KIF11 (0.37) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL4032657 | 0.74 | NR1H2 (0.42) | — | |
| SCHEMBL4032654 | 0.74 | NR1H2 (0.42) | — | |
| SCHEMBL23452363 | 0.72 | DRD2 (0.30) | DRD2DRD3 | |
| SCHEMBL21199457 | 0.72 | DRD2 (0.30) | DRD2DRD3 | |
| SCHEMBL21199459 | 0.72 | DRD2 (0.30) | DRD2DRD3 | |
| SCHEMBL28766813 | 0.71 | DRD2 (0.35) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL17242296 | 0.70 | SMYD2 (0.37) | DRD2DRD1DRD4DRD5DRD3 | |
| SCHEMBL25363324 | 0.70 | SMYD2 (0.37) | DRD2DRD1DRD4DRD5DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348440-B2 | Kinesin spindle protein (KSP) inhibitors, e.g., 4-(2,5-Difluorophenyl)-N-[(3S,4S)-3-fluoropiperidin-4-yl]-2-hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1N-pyrrole-1-carboxamide, and a carrier; antiproliferative and -carcinogenic agents; side effects reduction; used with an estrogen receptor modulator | MERCK & CO., INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-20060105997-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060105997-A1 | Mitotic kinesin inhibitors | KIF5B, KIF2C, KIF18B | RBP4 4495/4885DRD2 4648/4885DRD1 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.